Ultragenyx Pharmaceutical

Traded on the St. Petersburg Stock Exchange
Ultragenyx is a biopharmaceutical company involved in the R&D of novel products for treatment of rare and ultra-rare genetic diseases such as Angelman syndrome and X-linked hypophosphatemia.
Ultragenyx Pharmaceutical stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ultragenyx Pharmaceutical balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ultragenyx Pharmaceutical cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ultragenyx Pharmaceutical multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ultragenyx Pharmaceutical profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ultragenyx Pharmaceutical assets
Ultragenyx Pharmaceutical cash flows

Ultragenyx Pharmaceutical shares

TickerNameTypeNominal valueISINPrice
RARE:USUltragenyx Pharmaceutical, Inc.Common share-US90400D1081$50.43
Ultragenyx Pharmaceutical news
06.05.2022
Ultragenyx Pharmaceutical's GAAP loss for 3 months of 2022 was $152.32 million, up 11.9% from $136.141 million in the previous year. Revenue decreased 19.6% to $79.935 million from $99.395 million a year earlier.
Source: {source} pictogram ir.ultragenyx.com
Pictogram next
11.02.2022
Ultragenyx Pharmaceutical's GAAP loss for 2021 was $454.025 million, up 2.4 times from $186.566 million in the previous year. Revenue increased 29.7% to $351.406 million from $271.03 million a year earlier.
Source: {source} pictogram ir.ultragenyx.com
Pictogram next
03.11.2021
Ultragenyx Pharmaceutical's GAAP loss for 9M 2021 was $331.567 million, having doubled from $162.555 million in the previous year. Revenue increased by 49.3% to $268.017 million compared to $179.488 million a year earlier.
Source: {source} pictogram ir.ultragenyx.com
Pictogram next
03.08.2021
Loss of Ultragenyx Pharmaceutical on GAAP for 6 months of 2021 amounted to $258.569 million, increasing 2.8 times compared to $93.71 million in the previous year. Revenue increased 90.1% to $186.37 million from $98.018 million a year earlier.
Source: {source} pictogram ir.ultragenyx.com
Pictogram next
All Ultragenyx Pharmaceutical news
General information
Company nameUltragenyx Pharmaceutical
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Mailing address60 LEVERONI COURT NOVATO CA 94949
Websitewww.ultragenyx.com
Information disclosurewww.sec.gov